Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21972067 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL21972343 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL21905569 | 0.85 | STING1 (0.73) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL22044779 | 0.84 | STING1 (0.61) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL25809782 | 0.83 | STING1 (0.72) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL21990175 | 0.82 | STING1 (0.61) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL22043970 | 0.82 | STING1 (0.61) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL18864285 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL21972427 | 0.81 | STING1 (0.52) | SMN1; SMN2STING1TP53MAPTALDH1A1 | |
| SCHEMBL22044387 | 0.80 | STING1 (0.59) | SMN1; SMN2STING1TP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138827-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138827-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | SMN1; SMN2 4708/4885STING1 1/4885TP53 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.